|
|
|
| Efficacy of Tiotropium Bromide combined with Budesonide Formoterol in the treatment of chronic obstructive pulmonary disease |
| ZHU Yu-jun1 LIANG Qiu-hong2 |
| 1.Department of Respiratory,Yichun People′s Hospital,Jiangxi Province,Yichun 336000,China;2.Department of Infection,the Second People′s Hospital of Yichun City,Jiangxi Province,Yichun 336000,China |
|
|
|
| Guide |
|
|
Abstract Objective To investigate the efficacy of Tiotropium Bromide combined with Budesonide Formoterol in the treatment of chronic obstructive pulmonary disease (COPD).Methods A total of 88 patients with stable COPD admitted to Yichun People′s Hospital from January 2019 to January 2020 were selected and divided into two groups according to random number table method,44 cases in each group.The control group was treated with Budesonide Formoterol,and the observation group was treated with Tiotropium Bromide on the basis of the control group.The clinical efficacy,pulmonary function and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that in the control group,the difference was statistically significant (P<0.05).Forced expiratory volumone second (FEV1),forced vital capacity (FVC),FEV1/FVC,interleukin-6 (IL-6),tissue inhibitor of metalloproteinase-1 (TIMP-1) and transforming growth factor-β (TGF-β) between two groups before treatment were compared,the differences had no statistically significant (P＞0.05).After treatment 3 months,in the observation group,FEV1 was (2.71±0.45) mL,FVC was (3.11±0.39) mL,FEV1/FVC was (72.34±6.55)%,which were higher than those in the control of (2.26±0.43) mL,(2.57±0.19) mL,(62.21±7.51)%,after treatment 3 months,in the observation group,IL-6 was (15.06±6.03) ng/mL,TIMP-1 was (120.25±32.82) ng/mL,TGF-β was (79.54±9.24) ng/L,which were lower than those in the control group of (21.68±7.41) ng/mL,(145.11±33.18）ng/mL,(87.25±9.72) ng/L,the differences were statistically significant (P<0.05).There was significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Tiotropium Bromide combined with Budesonide Formoterol is effective in the treatment of COPD.It can improve the lung function and has high safety.It can be used as a safe and effective treatment for COPD patients.
|
|
|
|
|
| Fund: |
|
|
|
| [1] |
王俊，夏北平，刘巧丽.噻托溴铵联合布地奈德治疗哮喘-慢阻肺重叠综合征患者的临床疗效[J].中国医师杂志，2018，20（10）：1556-1558.
|
| [2] |
赵瑞芬，李霞，杨亚萍，等.噻托溴铵联合布地奈德/福莫特罗对慢性阻塞性肺疾病患者血管内皮功能及T淋巴细胞亚群的影响[J].心肺血管病杂志，2018，37（2）：98-102.
|
| [3] |
刘斌，冉献贵，邢青峰，等.噻托溴铵联合信必可都保治疗对慢阻肺患者肺功能和运动耐量及不良反应的影响[J].河北医学，2019，25（7）：1108-1112.
|
| [4] |
王新梅，栾念旭，靳岱红.噻托溴铵联合布地奈德福莫特罗治疗稳定期COPD 疗效及对细胞免疫功能的影响[J].中国医师杂志，2019，21（8）：1254-1256.
|
| [5] |
中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.慢性阻塞性肺疾病基层诊疗指南（2018年）[J].中华全科医师杂志，2018，17（11）：856-870.
|
| [6] |
韩娟，颜浩，徐淑晖，等.噻托溴铵联合布地奈德福莫特罗对慢性阻塞性肺疾病的疗效及对TGF-β、TIMP-1、IL-6水平的影响[J].现代生物医学进展，2018，18（13）：2531-2534，2544.
|
| [7] |
方佳，肖翔，李瑞金，等.噻托溴铵联合福莫特罗/布地奈德治疗哮喘-慢性阻塞性肺疾病重叠综合征的疗效分析[J].临床内科杂志，2018，35（3）：203-204.
|
| [8] |
夏文娟，王学中.布地奈德福莫特罗联合噻托溴铵对慢性阻塞性肺疾病急性加重期的临床疗效[J].安徽医学，2017，38（12）：1572-1574.
|
| [9] |
公维涛，孙杰，郭永忠.布地奈德福莫特罗单药与联合噻托溴铵治疗组COPD 对患者肺功能及生活质量的影响比较[J].贵州医药，2018，42（7）：46-47.
|
| [10] |
谭琳，岳春芽，蔡明文.福多司坦联合布地奈德福莫特罗粉吸入剂治疗稳定期慢性阻塞性肺疾病的临床研究[J].现代药物与临床，2018，33（12）：150-154.
|
| [11] |
成慧霞.补肺活血胶囊联合布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床，2019，34（12）：3589-3593.
|
| [12] |
胡晓晨，李静静，张建一，等.噻托溴铵与布地奈德应用于老年慢性阻塞性肺疾病模型大鼠的疗效比较[J].国际老年医学杂志，2018，39（4）：160-162.
|
| [13] |
李团政，杜世拔，陈荣，等.补气祛瘀中药联合布地奈德福莫特罗治疗慢性阻塞性肺疾病急性发作临床观察[J].中国中医急症，2017，26（8）：1493-1495.
|
| [14] |
曹晓琳，熊琴.噻托溴铵粉吸入剂联合不同剂量布地奈德混悬液雾化吸入治疗AECOPD 合并肺部感染的临床观察[J].解放军预防医学杂志，2019，37（4）：35-36.
|
| [15] |
李斯南，朱述阳，罗涛，等.吸入激素联合噻托溴铵治疗哮喘-慢性阻塞性肺疾病重叠综合征的效果及对血清炎症因子水平的影响[J].临床和实验医学杂志，2019，18（16）：1748-1751.
|
|
|
|
